One contribution of 18 to a discussion meeting issue 'Frontiers in epigenetic chemical biology'. DNA, RNA and histone methylation is implicated in various human diseases such as cancer or viral infections, playing a major role in cell process regulation, especially in modulation of gene expression. Here we developed a convergent synthetic pathway starting from a protected bromomethylcytosine derivative to synthesize transition state analogues of the DNA methyltransferases. This approach led to seven 5-methylcytosine-adenosine compounds that were, surprisingly, inactive against hDNMT1, hDNMT3Acat, TRDMT1 and other RNA human and viral methyltransferases. Interestingly, compound 4 and its derivative 2 showed an inhibitory activity against PRMT4 in the micromolar range. Crystal structures showed that compound 4 binds to the PRMT4 active site, displacing strongly the S-adenosyl-L-methionine cofactor, occupying its binding site, and interacting with the arginine substrate site through the cytosine moiety that probes the space filled by a substrate peptide methylation intermediate. Furthermore, the binding of the compounds induces important structural switches. These findings open new routes for the conception of new potent PRMT4 inhibitors based on the 5-methylcytosine-adenosine scaffold.
especially in modulation of gene expression [1, 2] . Methylation of deoxycytidines (dC) in DNA is the most stable epigenetic mark and occurs at CpG sites, which are grouped in islands and essentially located in promoters, repeated sequences and CpG island shores [3] . Hypermethylation of promoters induces gene silencing while hypomethylation is associated with gene expression [4] . The enzymes responsible for DNA methylation are the DNA methyltransferases (DNMTs). DNMTs add a methyl group on the carbon-5 (C5) position of the deoxycytidine at the CpG site in the DNA by using S-adenosyl-L-methionine (AdoMet/SAM) as methyl donor, like most of the methyltransferases (MTases) [5] . Alteration of DNA methylation patterns is associated with various diseases, such as cancer, and DNA methylation represents an attractive therapeutic strategy [6] .
Formerly DNMT2, now TRDMT1, structurally close to DNMTs, weakly methylates DNA at cytosine but rather methylates tRNA, especially cytosine 38 in the anticodon loop of aspartic acid tRNA [7] . tRNA methylation is implicated in metabolic activity of cancer cells and its inhibition has antiproliferative effects [8] . More globally RNA cytosine methylation functions are still unknown and newly studied. While only the C5 position of cytosine is methylated in DNA, the four bases of RNA ( pyrimidines U, C and purines G, A) are methylated at a large number of sites [9] . The study of the role of RNA methylation in diseases is emerging and the search for new inhibitors could result in chemical probes to study the biology of this modification [10] .
Histone methyltransferases (HMTs) catalyse the transfer of one, two or three methyl groups to lysine and arginine residues of histone proteins. Two major types of HMT exist, lysinespecific (HKMTs) and arginine-specific (PRMTs). In eukaryotic cells, histone methylation at certain sites is implicated in the condensation and decondensation of chromatin. We focused on the proteins arginine methyltransferases (PRMTs), a family containing nine members (PRMT1 to PRMT9) identified in mammalian cells [11, 12] . Expressed in nearly all mammalian cell types and tissues, PRMTs are involved in a wide variety of functional processes, like RNA processing, DNA damage and repair, cell signalling and most importantly transcription [13] [14] [15] . Moreover, arginine methylation of histones increases the complexity of the histone code by modulating the interaction of nuclear factors with other nearby histone marks.
Abnormal expression or activity of methylation-regulating enzymes has been noted in several types of human cancers, suggesting associations between histone methylation and malignant transformation of cells or formation of tumours [12, 16] . Therefore, there is an emerging interest in the discovery of new inhibitors of DNMTs, RNA MTases and PRMTs. In the case of transferases, a potent chemical strategy to design inhibitors is to use transition state analogues. Interestingly, DNMTs, RNA MTases and PRMTs all share the same methyl donor, the AdoMet/SAM, and, concerning the substrate that is methylated, cytosine, guanine and arginine share some common pharmacological features. We thus developed a convergent synthetic pathway to synthesize transition state analogues of the DNMT methylation reaction based on the coupling of cytosine analogues to adenosine. Such compounds can be useful chemical tools for structural studies. We explored their potential and selectivity toward several DNMTs, but also RNA MTases and PRMTs. Inhibition data revealed that such compounds unexpectedly failed to inhibit DNMTs and RNA MTases but rather inhibited PRMTs. Crystal structures of PRMT4 and PRMT6 in the presence of the compounds revealed that the compounds compete with the S-adenosyl-L-homocysteine (SAH) and occupy the two substrate pockets of the of PRMTs, the SAM and arginine pocket. Thus the 5-methylcytosine-adenosine scaffold resulted in a potent starting point for the conception of new inhibitors of PRMT4.
Methods (a) Chemicals
Commercial chemicals were from Sigma-Aldrich and Alfa-Aesar; oligonucleotides were bought from Eurogentec. The chemical synthesis and analysis of the conjugates are detailed in the electronic supplementary material. All compounds were prepared as 10 22 M aliquots in 100% DMSO, stored at 2208C and used as dilutions freshly prepared. -benzoyl-5-methylcytosine (8) synthesized according to [17] (500 mg, 2.18 mmol) in 70 ml of dichloromethane (DCM) was added N,O-bis(trimethylsilyl)acetamide (1.3 ml; 5.4 mmol), and the mixture was stirred at RT for 1 h. Methoxymethyl chloride (2.87 mmol) was added and the mixture was stirred for 18 h at RT. The solvent was removed and the residue was purified by silica gel chromatography using the eluent cyclohexane/ethyl acetate (4/6). Compound 9 was obtained as a white powder (554 mg; 2.03 mmol; 93% (
To a solution of 9 (550 mmol) in dry benzene (3 ml) under argon atmosphere were added N-bromosuccinimide (NBS) (125 mg; 720 mmol) and 2,2 0 -azobis(2-methylpropionitrile) (AIBN) (17 mg; 0.1 mmol) and the mixture was heated at 708C for 1 to 2 h. The reaction was followed by thin layer chromatography to prevent side product formation (cyclohexane/ethylacetate 4 : 6). After cooling, the solvent was removed by vacuum and the residue was co-evaporated with DCM twice. The crude product was used immediately without further purification.
To a 0.2 M solution of 11 or 12 in pyridine was added 2-nitrophenylsulfonyl chloride (2.5 eq.) portion-wise and the mixture was stirred at RT overnight. The solvent was removed by vacuum and the residue was purified by silica gel flash chromatography using a linear gradient of 1 N NH 3 
To a solution of derivative 13 or 14 (305 mmol) in N,N-dimethylformamide (DMF) (5 ml) was added K 2 CO 3 (126 mg; 915 mmol) and freshly prepared (S)-2-tert-butoxycarbonylamino-4-bromobutyric acid tert-butylester (125 mg; 369 mmol) and the mixture was stirred at RT for 6 h. Thiophenol (50 ml; 500 mmol) was added and the mixture was stirred at RT overnight. The mixture was filtered, the solvent removed by vacuum and the residue purified by silica gel flash chromatography using a linear gradient 0 ! 10% MeOH/NH 3 
Crude 10 was added to a solution of 15 or 16 (0.1 mmol) in DMF (3 ml) and N,N-diisopropylethylamine (DIPEA) (100 ml). After 1 h at RT, the mixture was diluted with ethyl acetate, the organic phase was washed with 1 M NaHCO 3 and brine, dried on MgSO 4 and the solvent was removed by vacuum. The residue was dissolved in 7 N NH 3 in MeOH and stirred at RT for 3 h.
The solvent was removed and the residue was purified by silica gel flash chromatography using a linear gradient of 1 N NH 3 
To a solution of derivative 13 or 14 (102 mmol) in DMF (2 ml) was added K 2 CO 3 (41 mg; 306 mmol) and freshly prepared 10 (350 mmol). The mixture was stirred at RT for 1 h. The mixture was diluted with ethyl acetate and washed with water. The organic phase was washed with brine and dried with MgSO 4 . Solvent was removed and the residue was dissolved in 7 N NH 3 in MeOH. The mixture was stirred at RT for 6 h. The solvent was removed under reduced pressure. The residue was dissolved in a suspension of K 2 CO 3 (41 mg; 306 mmol) in DMF (1 ml). Thiophenol (25 ml; 250 mmol) was added and the mixture was stirred at RT overnight, filtered and the solvent was removed. The residue was purified by reversed phase HPLC using a linear 0 ! 60% CH 3 CN gradient to obtain 19 (10 mg; 21 mmol; 21%) or 20 (17 mg; 36 mmol; 35%) as white foams. (20) 
Water ( (ix) 1-(Methoxymethyl)uracil (22) To a solution of uracil (21) (0.88 g; 7.93 mmol) in 250 ml of DCM was added N,O-bis(trimethylsilyl)acetamide (BSA) (4.8 ml; 19.4 mmol) and the mixture was stirred for 1 h at RT. Methoxymethyl chloride (MOMCl) (784 ml; 10.32 mmol) was added and stirred at RT for 18 h. The solvent was removed and the residue was purified by silica gel chromatography using the eluent cyclohexane/ethyl acetate (3 : 7) to give 22 (1.17 g; 7.53 mmol; 95%) as a white powder. 
To a solution of 1,2,4-triazole (138 mg; 2.0 mmol) and POCl 3 (60 ml; 0.65 mmol) in 1.5 ml of acetonitrile at 08C was added 280 ml of triethylamine (TEA) dropwise and the mixture was stirred at 08C for 40 min and then for 30 min at RT. Compound 22 (380 mg; 0.24 mmol) was added and vigorously stirred at RT overnight. The solvent was removed and 5 ml of 11 (65 mg; 0.20 mmol) or 12 (89 mg; 0.20 mmol) in MeCN was added. The reaction mixture was stirred for 6 h at RT. The mixture was diluted with ethyl acetate. The organic phase was washed with water and brine and dried over Na 2 SO 4 . The solvent was removed and the residue was purified by silica gel flash chromatography using a linear gradient of 1 N ammonia in methanol (0 ! 10% MeOH/NH 3 ) in DCM to afford 23 (42 mg; 94.6 mmol; 47%) or 24 (34 mg; 74.2 mmol; 37%) as a white powder. 2 0 ,3 (24) 
Water (50 ml) was added to a solution of adenosine-cytosine derivative 23 (27 mg; 60.8 mmol) or 24 (28 mg; 61.1 mmol) in TFA (0.5 ml) and stirred at RT for 2 h. The solvent was removed and the residues were co-evaporated three times with 1 N NH 3 in MeOH under reduce pressure. The residues were purified by rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 373: 20170072 reversed phase HPLC using a linear acetonitrile gradient with 0.2% TEA (0 ! 80% CH 3 CN). 
To a solution of adenosine derivative 13 (158 mg; 0.52 mmol) in 3 ml of DMF was added K 2 CO 3 (215 mg; 1.56 mmol) and 2-(Bocamino)ethyl bromide (140 mg; 0.63 mmol) and the mixture was stirred for 12 h at RT. The solvent was removed and the residue was purified by silica gel chromatography using a linear gradient 0 ! 10% MeOH/NH 3 
A solution of 25 (200 mg; 0.32 mmol) in dry TFA (0.5 ml) was stirred at RT for 1 h. The solvent was removed and the residue was purified by silica gel chromatography using a linear gradient 0 ! 10% MeOH/NH 3 (27) To a solution of triazole (276 mg; 4.0 mmol) and POCl 3 (120 ml; 1.29 mmol) in 3 ml of acetonitrile at 08C was added TEA
The solvent was removed and 5 ml of a solution of previously prepared 26 (134 mg; 250 mmol) was added and the mixture was stirred at RT for 6 h. The mixture was diluted with ethyl acetate. The organic phase was washed with water and brine and dried over Na 2 SO 4 . The solvent was removed and the residue was purified by silica gel flash chromatography using a linear gradient 0 ! 10% MeOH/NH 3 in DCM to afford 27 (81 mg; 0.12 mmol; 48%) as a white powder. 
To a solution of 27 (70 mg; 104 mmol) and K 2 CO 3 (43 mg; 31.3 mmol) in acetonitrile (0.5 ml) was added thiophenol (10 ml; 100 mmol) and the mixture was stirred at RT overnight. The mixture was filtered and the solvent was removed by vacuum. The residue was purified by silica gel chromatography using a linear gradient 0 ! 10% MeOH/NH 3 
Water (50 ml) was added to a solution of adenosine-cytosine derivative 28 (30 mg; 62 mmol) in TFA (0.5 ml) and the mixture was stirred at RT for 2 h. The solvent was removed and the residues were coevaporated three times with 1 N ammonia in methanol under reduced pressure. The residues were purified by reversed phase HPLC using a linear acetonitrile gradient with 0.2% TEA (0 ! 80% CH 3 CN). (c) Methyltransferase activity DNMT3A and DNMT1 assays were previously described [18, 19] and are detailed in the electronic supplementary material.
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The percentage of inhibition was calculated according to equation (2.1), where X is the signal determined in the absence of the inhibitor and Y is the signal obtained in the presence of the inhibitor:
TRDMT1 assays were conducted as described in [20] using inhibitor concentrations of 1 mM and 100 mM.
The RNA MTase filter binding assay (FBA) using various viral and cellular MTases was previously described [21 -23] . Briefly, FBA is based on the incubation of the RNA MTase at the corresponding concentration in the presence of the RNA substrate and the radiolabelled tritiated AdoMet ([ 3 H]SAM) in Tris-HCl pH 8 40 mM, DTT 1 mM, SAM 10 mM. Reaction mixtures were incubated for 20 min at 308C and stopped by adding a 10-fold dilution of the reaction mixture in 20 mM ice-cold AdoHcy (New England Biolabs). Samples were then transferred to diethylaminoethylcellulose (DEAE) filters (Perkin Elmer) by using a Filtermat Harvester apparatus (Packard Instruments). Unincorporated [ PRMT assays were carried out by Eurofins Scientific (France), based on the incorporation of radioactive methyl groups from [methyl-3 H]AdoMet on the corresponding peptide substrates in the presence of the human recombinant purified proteins [24 -27] 
(details in the electronic supplementary material).
Permeability studies were carried out by Eurofins Scientific (France) and are detailed in the electronic supplementary material.
PRMT crystallography studies: The Mus musculus PRMT4 gene sequence corresponding to the PRMT core (residues 130 to 487, MmPRMT4) [28] was obtained and M. musculus PRMT6 cloning, expression and purification were carried out as described previously [29, 30] , and are detailed in the electronic supplementary material.
(d) PRMT4 and PRMT6 crystallization and structure determination with the compounds
Compounds were solubilized in water before addition to the protein solution (2 mg ml 21 for PRMT4 and 6 mg ml 21 for PRMT6) at the final concentration of 2 mM for PRMT4 and 1 mM for PRMT6. The vapour diffusion method on hanging drop trays (VDX plate, Hampton Research) with a 1 ml reservoir was used for crystallization. Typically, 1 ml of protein-ligand solution was added to 1 ml of well solution consisting of 15-25% (v/v) PEG2000MME, 100 mM Tris-HCl pH 8.0 and 100 mM NaCl for PRMT4, and of 100 mM Tris-HCl or HEPES-NaOH pH 8.0, 200 mM NaCl and 10% (v/v) PEG 6000 for PRMT6. Crystals were grown at 208C and flash-frozen in liquid nitrogen after a brief transfer to 5 ml reservoir solution containing 15% (v/v) PEG400 as a cryoprotectant and were stored in liquid nitrogen.
Datasets were collected at the SOLEIL PROXIMA1 and ESRF ID23-2 beamlines, using a PILATUS 6M detector, PILATUS 2M-F (Dectris) or Q315 detector (ADSC), and processed with XDS [31] and HKL-2000 [32] . Five structures of MmPRMT4 were solved and refined. The crystals belong to the P2 1 2 1 2 space group with four MmPRMT4 molecules in the asymmetric unit (AU) or the P2 1 space group with eight MmPRMT4 molecules in the AU. Two structures of MmPRMT6 were solved and refined. The crystals belong to the I4 1 space group with one MmPRMT6 molecule in the AU. The structures were solved by molecular replacement using previously solved MmPRMT4 and MmPRMT6 structures.
Iterative cycles of model building and refinement were carried out using Coot [33] , PHENIX [34] and BUSTER [35] . A summary of the data statistics for the five solved and refined structures is provided in table 1. The atomic coordinates and experimental data have been deposited in the Protein Data Bank (PDB IDs: 5TBH, 5TBI, 5TBJ, 5LV2, 5LV3, 5LV4 and 5LV5). All structure figures were prepared with Cuemol (http://www.cuemol.org).
Results and discussion (a) Rational design
Recently, the transition state of DNMT1 has been characterized by means of experimental kinetic isotopic effects showing that the transfer of the methyl group is the rate-limiting step [37] . Thus, in order to mimic the transition state of the methylation reaction catalysed by the DNMTs (figure 1a), we coupled the adenosine moiety of the AdoMet cofactor to a cytosine analogue methylated at position 5. Position N1 of the cytosine ring was substituted by a methoxymethyl group (MOM) to mimic the sugar. We kept the amino acid substituent of the AdoMet, the methionine, replaced the sulfur atom by nitrogen to increase chemical stability and varied the length of the N-alkyl chain, affording compounds 1 and 2 (figure 1b).
Next we omitted the amino acid substituent (3 and 4, figure 1c ) and explored the attachment to the amine on position C4 of the cytosine and the length of the N-alkyl chain between the cytosine and the adenosine (5, 6 and 7, figure 1c ).
(b) Chemistry
The synthesis of these analogues required the optimization of a specific pathway because of the uncommon chemical reactivity of the cytosine base compared with thymine. The key step was the development of a convergent synthetic pathway starting from the protected bromomethylcytosine derivative 10 (scheme 1). Owing to its high reactivity, position N1 of the cytosine derivative 8 was substituted by a methoxymethyl group (MOM) in order to avoid polymerization. This MOM group was chosen because it can also mimic a fragment of the sugar moiety. Amine derivatives 1 to 4 were obtained by N-alkylation by cytosine bromide derivative 10 (scheme 1) of adenosine derivatives. The key synthon 9 was freshly prepared under Vorbrü ggen conditions from the protected 5-methylcytosine derivative 8 which was obtained following the procedure described by Buchini et al. [17] . An N1-alkylation with a MOM group was performed to obtain derivative 9. Then radical bromination in the benzylic position of 9 was achieved with N-bromosuccinimide (NBS) and 2,2 0 -azo-bis-isobutyronitrile (AIBN) leading to the desired unstable bromide 10, which was used immediately without any purification.
Transition state analogues 1 and 2 were synthesized starting from amines 11 and 12 described previously [38, 39] , which were protected by addition of 2-nitrophenylsulfonyl chloride, affording the nosylated derivatives 13 and 14 (scheme 2). They were alkylated by (S)-2-tert-butoxycarbonylamino-4-bromobutyric acid tert-butylester [40] in the presence of TEA, then treated with thiophenol to remove the nosyl protective group to give 15 and 16. The secondary amines 15 and 16 were alkylated by the protected bromomethylcytosine 10 in the presence of K 2 CO 3 , followed by treatment with ammonia in methanol to remove the benzoyl group of the cytosine moiety, leading to 17 and 18, respectively. The compounds 1 and 2 were obtained from compounds 17 and 18 after cleavage rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 373: 20170072 of the protective groups upon TFA/water treatment. Since the deprotected group compounds were difficult to purify, we chose to first isolate compounds 17 and 18 at high purity and to cleave all the acid-labile protective groups only in the final step. Most importantly, in the synthetic pathway, the choice of the nosyl group was crucial because of its ability to play a double role of activating and protecting group [41] . A direct N-alkylation of the primary amines 11 and 12 was tried first but provided the unprotected secondary amine with a very poor yield, even upon use of caesium hydroxide as base, Table 1 . X-ray data collection and refinement statistics. Statistics for the highest-resolution shell are shown in parentheses. The resolution limits for I/s(I which is known to induce a chemoselectivity in secondary amine formation [42] . In contrast, the use of the nosyl group afforded more than 64% yield over the three steps of protection, coupling and deprotection.
Compounds 3 and 4, lacking the amino acid moiety, were obtained using the same synthetic pathway (scheme 2) by N-alkylation of the nosylated derivatives 13 and 14 with the protected bromomethylcytosine 10 in the presence of K 2 CO 3 , followed by ammonia treatment in methanol to remove the benzoyl group of the cytosine moiety and then thiophenol treatment, affording compounds 19 and 20. Treatment with TFA in water afforded the desired bisubstrate analogues 3 and 4. Of note, the order of the deprotection steps is crucial: the benzoyl protective group had to be removed first because we observed that the presence of the secondary amine made it difficult to remove. Indeed, the presence of an NH group on the C5 methyl group of the cytosine moiety seems to stabilize the benzoyl protective group on the amine at the C4 position. Neither NH 3 nor KOH in methanol or water at RT or under reflux removed the benzoyl group.
Analogues 5 and 6, linked to the adenosine moiety by the N4 position of cytosine, were obtained starting from amines 11 and 12 (scheme 3). N1-MOM-protected uracil derivative 22 was prepared from uracil (21) using the same conditions as for 9 (scheme 1). Next, 22 was activated with 1,2,4-triazole and POCl 3 in the presence of TEA and reacted with the amine derivatives 11 and 12 to afford compounds 5 and 6, respectively, after removal of the isopropylidene groups of intermediates 23 and 24 upon acidic treatment.
Finally, analogue 7, containing an ethyl spacer between the adenosine and the cytosine moieties, was obtained from nosylated 13, which was N-alkylated by 2-(Boc-amino)-ethyl bromide to give 25 (scheme 3). After Boc-deprotecting by TFA, the obtained amine 26 was reacted with activated uracyl derivative 22 to give 27. Desired compound 7 was obtained under acidic conditions from 28 obtained after deprotection of 27 by thiophenol.
(c) Biological activity
Compounds 1 to 7 were tested for their ability to inhibit the methylation of DNA duplexes by human catalytic DNMT3A2 and full length DNMT1 using the assays previously developed [19] . None of the compounds, even compounds 1 and 2, which rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 373: 20170072 mimic more closely the major transition state of DNMTs [37] , was found to be effective in inhibiting hDNMT3Acat and hDNMT1 (table 2) . This is surprising, since Wahhab and colleagues observed a strong inhibition of DNMT1 and DNMT3b2 (IC 50 , 10 mM) with amino AdoHcy derivatives, in which the 5 0 amine group of the adenosine was functionalized with a benzyl substituent such as 4-nitrobenzyl group [43] [44] [45] .
Next, we tested the compounds for their ability to inhibit TRDM1, since this cytosine RNA MTase is structurally related to the DNMTs, being discovered by sequence homology to the DNMTs and once called DNMT2 till it was discovered that it methylated RNA [7, 8] . Only compound 1, the transition state amino analogue bearing the amino acid group, showed some inhibition at a high concentration of 1 mM (table 2) with an inhibition activity of 20% at 100 mM. This incited us to screen the compounds against several viral and human RNA MTases involved in the methylation of the RNA cap structure. These MTases have been previously shown to methylate cap structure either at the N7 position of guanine (WNV-MTase, MERS-N7-MTase, SARS N7-MTase, hRNMT) or/and at the 2 0 OH position of the first nucleotide ribose (WNV-MTase, MERS 2 0 O-MTase, SARS 2 0 O-MTase, DV MTase). Again only the amino acid derivatives showed some inhibitory potency at 50 mM, in particular compound 1, against hRNMT.
Next the compounds were screened against selected human PRMTs (table 3) , identified to play a role in cancer development and maintenance, and co-crystallization studies were performed with compounds 1, 2, 3, 4 and 7 with an isolated catalytic domain of MmPRMT4 (residues 130 to 487) [46, 47] or with PRMT6 [30] . Interestingly, compound 2 and its analogue 4 showed an activity against PRMT4, also called coactivatorassociated arginine methyltransferase 1 (CARM1), and some activity against PRMT7 (table 3) . IC 50 values against PRMT4 of 1.9 and 14 mM were measured for 4 and 2, respectively. The structural data brought insights on how the 5-methylcytosineadenosine transition state analogues inhibit the PRMTs.
(d) Structural insights on the inhibition of PRMTs
Concerning PRMT4, except for compound 2, high-resolution crystal structures were obtained and the structures were solved and refined in two closely related space groups P2 1 2 1 2 and P2 1 as seen for the MmPRMT4 catalytic domain. The orthorhombic space group contains one copy of the PRMT4 tetramer in the asymmetric unit, while the monoclinic space group has two PRMT4 tetramers in the asymmetric unit (table 1) .
These co-crystal structures revealed that the compounds are able to displace the SAH. The purified MmPRMT4 construct naturally contains SAH molecules bound in the active site. By comparing the PRMT4-compound structures with PRMT4 -SAH structures (PDB ID: 5IH3), two classes of compounds can be defined: (i) that displacing all SAH molecules natively bound to the PRMT4 (compound 4) and (ii) those partially displacing the SAH molecules (compounds 1, 3 and 7). The compounds bind to the PRMT active site and occupy the two substrate binding sites (figure 2): the SAM cofactor and the arginine site (to be methylated)-the cytosine moieties probing the space filled by a substrate peptide Table 2 . Screening for inhibitory potential of transition state analogues against DNA and RNA MTases. The percentage of inhibition of the enzymatic activity is reported for experiments run in duplicates. -, not determined. figure S1 ). For all inhibitors, the interactions with the base and sugar moieties are strictly conserved and identical to what is observed for SAH [46] .
(i) Strong inhibition of PRMT4 by analogue 4
Compound 4 shows the strongest potency against PRMT4 in the inhibition assays. It lacks the amino acid moiety and it is distant from the 5 0 position of the adenosine by an additional carbon. In the co-crystal structure, the cytosine moiety occupies the place of the target arginine (figure 2a; electronic supplementary material, figure S1c,d). Binding of 4 induces the concerted movement of mainly five residue side chains, Gln159, Met163, Arg169, Glu258 and His415 (figure 2b and electronic supplementary material, figure S2 ). All PRMTs share a common active site architecture defined by specific amino acids (belonging to the so-called motifs I to IV) known to be key for catalysis [11] [12] [13] 49, 50] . Glu258 belongs to the double-E loop (motif 3) and His415 to the THW loop (motif 4), conserved residues crucial for catalysis by all PRMTs. Arg169 is also conserved in all PRMTs as it interacts with the carboxylate atoms of the SAM/SAH, and Met169 is conserved in all type-I PRMTs. Gln159 is a crucial residue, only present in PRMT4 sequences, and here interacts by two hydrogen bonds with the cytosine moiety (figure 2b and electronic supplementary material, figure S1c,d). This latter interaction seems to be the driving force for the observed inhibition selectivity of the compounds on PRMT4.
(ii) The other compounds Of note, compound 2 differs from 4 by the presence of the amino acid moiety, which results in a decrease of inhibition (1.9 to 14 mM for IC 50 ). However, no co-crystal structure could be obtained with PRMT4.
Compounds 1, 3 and 7 are weak inhibitors of PRMT4 (table 3) and displaced only 50% of the naturally bound SAH molecules on PRMT4 (only one SAH is replaced by the compound per dimer, figure 3 ). Compounds 1 and 3 are derivatives of 2 and 4, respectively, but with only one carbon atom in the linker between the sugar and the nitrogen atom, while 7 is branched through position N4 of the cytosine. In the case of all three compounds, the co-crystal structures show that the cytosine moiety goes less deep into the arginine substrate binding site (overlay of the bound compounds in the co-crystal shown in electronic supplementary material, figure S2 ), which can also partly explain the reduced inhibition. In addition, the co-crystals with 1 (figure 3a,b) and 7 (figure 3c,d) reveal that binding of each compound produces no conformation changes except a small reorientation of Gln159 and a different water molecule network (electronic supplementary material, figure  S3 ). In contrast, the weakest inhibitor compound 3 induces conformation changes of three residues, His415, Arg169 and Arg169 side chains, involved in the interaction with the cytosine moiety as shown by compound 4 (figure 3e,f and electronic supplementary material, figure S3 ).
(iii) Complementary insights from PRMT6 co-crystals
Only compounds 1 and 2 bearing the amino acid moiety were able to co-crystallize with PRMT6. The two compounds differ by the length of the link between the sugar and the nitrogen. The cytosine moiety has very similar conformations for both compounds and their binding is without any conformational changes compared with SAH binding on PRMT6 ( figure 4 and electronic supplementary material, figure S4 ), explaining the inhibitory data (table 3) .
(e) Cancer cell experiments
Because of the role of PRMT4 in breast, colon and prostate cancer, we tested compounds 2 and 4 in prostate DU145, colon HCT116 and breast MCF7 cancer cell lines. These cell lines were treated with 2 and 4 at 1 and 10 mM and analysed after 3, 7 or 11 days of treatment. The compounds did not alter the proliferation of the cells (electronic supplementary material, figure S5 ) and compound 4 had no effect on the methylation of H3R17, a substrate of PRMT4, even after 11 days of treatment (electronic supplementary material, figure  S6 ). In view of the elevated polar surface area of compound 4, permeability studies were further carried out in Caco-2 cells. The apparent permeability coefficient (P app ) was , demonstrating a lack of efflux through the P-gp transporter. Both P app values are in agreement with a very poor ability of compound 4 to cross the cell membrane. As a result, the lack of antiproliferative activity of compound 4 is most likely due to poor target engagement due to low concentration levels of the chemical entity in the intracellular medium. 
Conclusion
In conclusion, we developed a convergent synthetic pathway starting from a protected bromomethylcytosine derivative to obtain transition state analogues of the DNMTs bearing a 5-methylcytosine scaffold linked to adenosine via an N-alkyl linker. This approach led to seven cytosine-adenosine compounds that were, surprisingly, inactive against hDNMT1 and hDNMT3Acat. Three reasons could explain this: either (1) the inability of the analogues to enter the pocket and displace the cofactor, or (2) their geometry-for example the work of Du et al. [37] suggests that an sp 3 configuration of the C5 carbon of the cytosine moiety could be necessary instead of the sp 2 configuration of 1 to 4, or (3) the distances of the bonds do not align with the transition state complex. Further analogues will be needed to test these hypotheses. The compounds were also tested against several RNA MTases, such as TRDMT1, structurally closely related to the DNMTs, and viral RNA MTases. Weak activity was observed for a transition state analogue containing the amino acid side chain.
We next screened the compounds against several PRMTs, selected for their potential role in cancer. Interestingly, compound 4 and its derivative 2 showed inhibitory activity against PRMT4 at the micromolar level.
Crystal structures of PRMT4 and PRMT6 in the presence of the compounds revealed that some inhibitors displace totally (compound 4) or partially (compounds 3 and 7) the SAM cofactor from the PRMTs (figures 2-4) . The four co-crystal structures of PRMT4 (PRMT4-4, PRMT4-3, PRMT4-7, PRMT4-1) and two co-crystal structures of PRMT6 (PRMT6-2, PRMT6-1) revealed the following. First, the compounds bind to the PRMT active site and occupy the two substrate binding sites: the SAM and the arginine site (to be methylated) (electronic supplementary material, figure S1 ). Most interestingly, the cytosine moiety fills in the space left by the arginine, explaining the inhibition data and confirming our working hypothesis (electronic supplementary material, figures S3 and S4). Second, five structural switches are involved in the strongest in vitro inhibition. These conformation changes involve residues strongly conserved in type-I PRMTs and amino acids specific to PRMT4.
Interestingly, increasing evidence shows the specific involvement of PRMT4 in promoting tumorigenesis in solid and haematological cancers [9, [51] [52] [53] [54] [55] [56] . Thus the discovery of small molecule inhibitors of PRMTs has been the focus of many studies during the last years and several compounds have been described [24, 25, 29, [57] [58] [59] [60] [61] . High-throughput screening efforts led to the identification of pyrazole and benzimidazole derivatives as potent PRMT4 inhibitors, the most potent showing IC 50 values of 27 and 30 nM [61] . These inhibitors bind to the substrate arginine-binding cavity of PRMT4 but require the presence of bound SAH. Among the mimics of the SAM scaffold and more particularly the bisubstrate analogues designed to simultaneously occupy substrate and cofactor binding sites ( [62] for review), the most potent and specific inhibition shows nanomolar range IC 50 values [60] .
Here we identified a new scaffold derived from the design of transition state analogues of the DNMTs to inhibit PRMTs and in particular PRMT4. Compound 4 is able to displace the four bound SAH molecules from the catalytic site and the cytosine moiety to occupy the space filled by the substrate peptide methylation intermediate, inducing crucial structural changes. The scaffold has not been optimized and further pharmacophoric modulations are needed to increase the potency and selectivity. The co-crystal structures highlighted the chemical modifications that can be done and will guide the optimization. In addition the cellular penetration properties need improvement to obtain an effect in cancer cells. These findings open new routes for the conception of new PRMT4 inhibitors based on the 5-methylcytosine scaffold.
Data accessibility. All structures and structure factors have been deposited in the Protein Data Bank (PRMT4-1: 5TBH; PRMT4-3: 5LV2; PRMT4-7: 5TBI; PRMT4-4: 5TBJ, PRMT6-1: 5LV4, PRMT6-2: 5LV5). 
